Valuation: Cipher Pharmaceuticals Inc.

Market Cap 337M 239M 213M 197M 179M 22.65B 342M 2.36B 928M 11.84B 896M 877M 37.85B P/E 2026 *
11.8x
P/E 2027 * 10.9x
Enterprise Value 337M 239M 213M 197M 179M 22.65B 342M 2.36B 928M 11.84B 896M 877M 37.85B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.14x
Free-Float
57.46%
Yield 2026 *
-
Yield 2027 * -
1 week-2.93%
Current month-2.93%
1 month-9.68%
3 months-19.21%
6 months-27.40%
Current year-12.02%
1 week 13.25
Extreme 13.25
13.78
1 month 13.25
Extreme 13.25
14.77
Current year 13.25
Extreme 13.25
20.56
1 year 12.48
Extreme 12.48
20.56
3 years 4.3
Extreme 4.3
20.56
5 years 1.54
Extreme 1.54
20.56
10 years 0.38
Extreme 0.38
20.56
Manager TitleAgeSince
Chief Executive Officer - 2019-07-28
Director of Finance/CFO - 2024-08-09
Director of Finance/CFO - 2022-08-14
Director TitleAgeSince
Chairman - 2019-06-11
Director/Board Member 78 2023-06-20
Director/Board Member - 2023-06-20
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 TaxCompany -133,245 0.5243%
9/30/26 TaxCompany 133,245 0.5243%
9/29/26 Option

Director

5,000 0.0197%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-2.93%-9.86%+195.10% 238M
-1.33%+5.18%+54.50%+104.26% 1,120B
-0.69%-2.93%+31.35%+66.17% 616B
-0.96%+2.25%+23.13%+89.36% 504B
+0.24%+6.23%+33.98%+52.38% 367B
-1.59%-1.35%+69.39%+40.83% 360B
-0.40%+4.28%+19.17%+42.51% 288B
-0.37%+3.35%-1.26%+16.85% 258B
-1.75%+2.43%+42.21%+49.85% 234B
-2.00%+1.26%+24.64%+92.13% 194B
Average -0.21%+2.69%+28.73%+74.94% 394.11B
Weighted average by Cap. -0.47%+3.52%+37.89%+71.73%

Financials

2026 *2027 *
Net sales 70.85M 50.19M 44.8M 41.52M 37.75M 4.77B 71.97M 498M 195M 2.49B 188M 184M 7.96B 81.35M 57.63M 51.44M 47.67M 43.35M 5.47B 82.64M 571M 224M 2.86B 216M 212M 9.14B
Net income 27.7M 19.62M 17.51M 16.23M 14.76M 1.86B 28.14M 195M 76.35M 974M 73.68M 72.1M 3.11B 31.76M 22.5M 20.08M 18.61M 16.92M 2.14B 32.26M 223M 87.55M 1.12B 84.48M 82.68M 3.57B
Net Debt - -
Projected Income Statement - Annual - Cipher Pharmaceuticals Inc.
Logo Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products, manages the required clinical development and regulatory approval process, and markets those products either directly or indirectly in Canada, the United States and South America. The Company's product categories include dermatology, hospital acute care, out‑licensed, and specialty medicine. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Absorica (isotretinoin) is an oral retinoid. Durela, its specialty medicine, is an opioid analgesic indicated for the management of moderate to moderately severe pain in adults who require continuous treatment for several days or more. Its pipeline products include Piclidenoson CF-101, MOB-015 and DTR-001.
Employees
5
Date Price Change Volume
26-10-19 $13.25 0.00% 8,408
26-10-16 $13.25 -2.07% 12,924
26-10-15 $13.53 +1.35% 9,101
26-10-14 $13.35 -1.11% 11,548
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cipher Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.25CAD
Average target price
19.45CAD
Spread / Average Target
+46.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Cipher Pharmaceuticals Inc.